Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.

@article{Pautier2002CisplatinbasedCR,
  title={Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.},
  author={Patricia Pautier and Catherine Genestie and Karim S Fizazi and Philippe Morice and Catherine Mottet and Christine Haie-meder and Axel le Cesne and Catherine Lhomm{\'e}},
  journal={International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
  year={2002},
  volume={12 6},
  pages={749-54}
}
Uterine sarcomas are an extremely rare event. There is no standard therapy for cases of relapse, although chemotherapy is commonly used. We studied the use of a cisplatin-based chemotherapy regimen for uterine sarcomas with an unusually long follow-up. Thirty-nine women with a median age of 50 years (32-71) entered the study. Histologically, leiomyosarcomas (26), carcinosarcomas (8), and stromal sarcomas (5) were represented. Group 1 consisted of patients undergoing adjuvant therapy (for… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Twenty blood transfusions in 10 patients and 12 platelet transfusions in seven patients were required .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
One toxicity - related death ( hemorrhage ) occurred .
One toxicity - related death ( hemorrhage ) occurred .
DECAV therapy consisted of doxorubicin 50 mg / m2 d1 , dacarbazine ( DTIC ) 200 mg / m2/d d1 - 3 , vindesine 2 mg / day d1 - 2 , cisplatin 100 mg / m2 d3 , and either cyclophosphamide ( CPM ) 200 mg / m2/d d1 - 3 ( n = 21 ) , or ifosfamide ( IFM ) 2 g / m2/d d1 - 3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia ( nine patients ) , including 13 cases of febrile neutropenia .
Histologically , leiomyosarcomas ( 26 ) , carcinosarcomas ( 8) , and stromal sarcomas ( 5 ) were represented .
Histologically , leiomyosarcomas ( 26 ) , carcinosarcomas ( 8) , and stromal sarcomas ( 5 ) were represented .
Twenty blood transfusions in 10 patients and 12 platelet transfusions in seven patients were required .
Twenty blood transfusions in 10 patients and 12 platelet transfusions in seven patients were required .
Twenty blood transfusions in 10 patients and 12 platelet transfusions in seven patients were required .
Histologically , leiomyosarcomas ( 26 ) , carcinosarcomas ( 8) , and stromal sarcomas ( 5 ) were represented .
All Topics